AN OBSERVATIONAL PROSPECTIVE RESEARCH ON THE PREDICTIVE FACTORS, TRANS ARTERIAL CHEMOEMBOLIZATION WITH ASSOCIATED ADVERSE EVETS OF HEPATOCELLULAR CARCINOMA

Objective: The objective of this research was the documentation of the adverse effects of the prediction of the factors and trans arterial chemoembolization. Methods: Our research was observational prospective held at Urology Department, Allied Hospital, Faisalabad (Nov, 2016 to Nov, 2017). We studied the hepatocellular carcinoma patients who developed related complications in the first six weeks of the procedure and documented every detail. Data analysis was made on SPSS software. Results: Research sample included eighty patients with 59 males (73.8%) and remaining female with an age bracket of 28 – 76 years (Mean age as 52.25 ± 9.24) years. Hepatitis C was the common etiology with associated fifty-five cases of cirrhosis (68.8%), 46 adverse effects cases (57.5%), 37 cases of post trans arterial chemoembolization syndrome (46.3%). No additional complications were observed in 24 syndrome cases (64.8%); whereas, 3 renal dysfunction cases (8%), 2 hypertensive crises (5%) and one case of urinary tract infection (UTI) (2.7%), sepsis and pneumonia. Six cases of cirrhosis decompensation (7.5%) among those three died because of sepsis (50%). There was an association of the syndrome with the tumor size (above 5 cm, P-value = 0.001) and higher lipiodol dose P-value as 0.0001. Cirrhosis decompensation was linked with the low basal albumin, an advanced basal child Turcotte Pugh and end-stage liver disease model with respective (P-value = 0.002), (P-value = 0.005) and (P-value = 0.006). Conclusion: Trans arterial chemoembolization is generally considered as safe but it may also lead into advanced liver disease complications as well. There is an association of the post-procedure syndrome with the increased size of the tumor and dose of the lipiodol. Keywords: Hepatocellular carcinoma, Post TACE Syndrome, Lipiodol, Tumor, Syndrome and Adverse events